RA

Ram Avtar Chhaba

Active Director Director DIN 06449645
DIN 06449645 First appointment Dec 2012 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 4 active board seats
Past companies 3 historical roles
Total affiliations 7 Since Dec 2012
Shareholding value •••• Premium profile

About Ram Avtar Chhaba

Data last updated:

Ram Avtar Chhaba is a Director at Nexkem Pharmaceuticals Private Limited (since 2021), Director at Nexkem Biotech Private Limited (since 2020) and Director at Nexkem Foundation (since 2023), and holds 1 more current directorship. The companies operate in Pharma and Chemicals and Materials. The 2 current companies with reported revenue have a combined latest revenue of ₹30.83 Cr; the largest is Nexkem Pharmaceuticals Private Limited at ₹22.48 Cr (FY 2025). Earlier, Ram Avtar Chhaba was a Director at Aditya Petromax Private Limited (2012–2014) and Director at Ethics Drugs (India) Private Limited (2020–2021) and 1 more.

DIN 06449645
Primary Designation Director
Industry Pharma
First Appointment 12 Dec 2012
Oldest Company Age 10 yrs
Largest company Nexkem Pharmaceuticals Private Limited · ₹22.48 Cr (FY 2025)
Combined revenue ₹30.83 Cr across 2 companies

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director24 Aug 20212016₹22.48 Cr (FY 2025)Active
Nexkem Biotech Private Limited U24233HP2020PTC008107
Director25 Sep 20202020₹8.35 Cr (FY 2025)Active
Nexkem Foundation U88900PB2023NPL058137
Director10 Apr 20232023Active
Director24 Aug 20202020Active

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Aditya Petromax Private Limited U23209RJ2011PTC036550
Director12 Dec 20122011Strike Off
Ethics Drugs (India) Private Limited U24239RJ2020PTC068391
Director26 Feb 20202020Active
Nexline Pharma Private Limited U24200RJ2020PTC067688
Director07 Jan 20202020₹1.04 Cr (FY 2025)Active

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Nexkem Biotech Private Limited
Nexkem Pharmaceuticals Private Limited
Nutrock Nutrition (India) Private Limited
Nexkem Foundation
Premium access

Shareholding and investment profile for Ram Avtar Chhaba

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Ram Avtar Chhaba

Ram Avtar Chhaba currently holds 4 directorships: Nexkem Pharmaceuticals Private Limited (Director, since 24 Aug 2021, revenue ₹22.48 Cr (FY 2025)); Nexkem Biotech Private Limited (Director, since 25 Sep 2020, revenue ₹8.35 Cr (FY 2025)); Nexkem Foundation (Director, since 10 Apr 2023); Nutrock Nutrition (India) Private Limited (Director, since 24 Aug 2020).

Ram Avtar Chhaba was first appointed on 12 Dec 2012 as Director at Aditya Petromax Private Limited. The most recent appointment on record is 10 Apr 2023 at Nexkem Foundation.

The 2 current companies of Ram Avtar Chhaba that report revenue have a combined latest revenue of ₹30.83 Cr: Nexkem Pharmaceuticals Private Limited ₹22.48 Cr (FY 2025); Nexkem Biotech Private Limited ₹8.35 Cr (FY 2025).

Ram Avtar Chhaba held 3 earlier board appointments: Aditya Petromax Private Limited (Director, 12 Dec 2012 to 07 Jul 2014); Ethics Drugs (India) Private Limited (Director, 26 Feb 2020 to 18 Aug 2021); Nexline Pharma Private Limited (Director, 07 Jan 2020 to 03 Sep 2020).

The current boards of Ram Avtar Chhaba's companies include Sunita Chhaba (Nexkem Pharmaceuticals Private Limited), Devendra Singh Dagur (Nexkem Biotech Private Limited), Ashish Chhaba (Nutrock Nutrition (India) Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available